Aerie Pharmaceuticals

Paratus Sciences Appoints Theresa Heah, M.D., M.B.A. as Chief Executive Officer

Retrieved on: 
Wednesday, February 21, 2024
Therapy, Ophthalmology, ESMT, Biotechnology, Aerie Pharmaceuticals, Inflammation, Management, Drug development, Bayer, Drug discovery, Polaris Partners, European School, University, Intergalactic, Disease, Applied Genetic Technologies Corporation, AAV, Human, Pharmaceutical industry

“We are thrilled to have Dr. Heah assume the helm at Paratus,” said Amir Nashat, Executive Partner of Polaris Partners, chair of Paratus’s Board of Directors and the company’s founding CEO.

Key Points: 
  • “We are thrilled to have Dr. Heah assume the helm at Paratus,” said Amir Nashat, Executive Partner of Polaris Partners, chair of Paratus’s Board of Directors and the company’s founding CEO.
  • “Theresa brings a tremendous wealth of experience as a seasoned pharma and biotech executive, having spearheaded the development and commercialization of multiple innovative therapies.
  • She most recently served as the Chief Executive Officer and President of Intergalactic Therapeutics, a non-viral gene therapy platform company.
  • Under Amir’s leadership, Paratus has made important progress advancing this premise into a state-of-the-art R&D engine.

Aeries Technology, Inc. Announces Two Executive Appointments

Retrieved on: 
Monday, November 13, 2023
Consulting, Asset Management, Professional Services, Finance, Sale, Freescale Semiconductor, MakeMyTrip, UST (company), Carvana, Lightower Fiber Networks, Record, Acquisition, Sidera Networks, Bachelor of Technology, Zulily, Paytm, Head, Investment, HarbourVest Partners, History, FP, Columbia Business School, Bank, Crediton, Brigham Young University, GE Capital, Pinterest, Delivery Hero, Master of Accountancy, IIT Kharagpur, Thrillist, Credit, IPO, MBA, Integral Ad Science, Internet, Growth, Family, Momentive (software company), AI, Microsoft, Bank of America, Innovation system, Corporate finance, Arista Networks, Initial public offering, Trivago, Management, Plarium, Citigroup, Costar, Aerie Pharmaceuticals, Purple, Grubhub, Dosh, Walmart, Intuit, Fiverr

“I am thrilled to welcome both Rajeev and Daniel to the Aeries family,” said Sudhir Panikassery, Chief Executive Officer and Co-Founder of Aeries.

Key Points: 
  • “I am thrilled to welcome both Rajeev and Daniel to the Aeries family,” said Sudhir Panikassery, Chief Executive Officer and Co-Founder of Aeries.
  • Previously, he served as the Chief Financial Officer of McLaren Technology Acquisition Corp. from 2021 to 2023, helping to lead their IPO and raising $205 million.
  • Mr. Nair earned his MBA from Columbia Business school and his Bachelor of Technology from IIT Kharagpur.
  • As an investment banker and private equity investor, he worked on transactions totaling approximately $40 billion in transaction value for disruptive technology companies.

Walgreens Boots Alliance Reports Fiscal 2023 Third Quarter Results

Retrieved on: 
Tuesday, June 27, 2023
Discount, Variety, Seniors, Other Retail, Convenience Store, Health, Consumer, Pharmaceutical, General Health, Retail, Operating cost, Walgreens Boots Alliance, Walgreens, Prescription, GAAP, Tobacco, Cardinal Health, Acquisition, Investment, Patient, SVP, CityMD, Risk, Vaccination, Physician, Summit Health, WBA, Net, Aerie Pharmaceuticals, Growth, Security (finance), Medco Health Solutions, Pressure, Pharmacy, International, COVID-19, Variable, Healthcare in the United States, CFO, Partnership, SG, Comparable, Calendar, EmblemHealth, COVID, Sale, Public expenditure, EBITDA, OTC, EPS, Summit, Management, Pharmaceutical industry, Aquaculture, Health care, Music, Real estate, Cryptocurrency, Sales, Video game, Risk management, Bank, Shield, Boots (company), AmerisourceBergen

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced financial results for the third quarter of fiscal 2023, which ended May 31, 2023.

Key Points: 
  • Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced financial results for the third quarter of fiscal 2023, which ended May 31, 2023.
  • Operating loss was $0.5 billion in the third quarter compared to a loss of $0.3 billion in the year-ago quarter.
  • Earnings per share in the third quarter was $0.14, compared to EPS of $0.33 in the year-ago quarter.
  • Boots UK comparable retail sales increased 13.4 percent compared to the year-ago quarter, growing market share for the ninth consecutive quarter.

I-Mab Announces the Appointment of Raj Kannan as CEO

Retrieved on: 
Thursday, June 22, 2023
Growth, Aerie Pharmaceuticals, Patient, Pharmaceutical industry, Fine chemical

This appointment serves as a significant step towards further realizing I-Mab's mission of delivering transformative therapies to patients worldwide.

Key Points: 
  • This appointment serves as a significant step towards further realizing I-Mab's mission of delivering transformative therapies to patients worldwide.
  • Raj Kannan has over 30 years of industry experience in creating and developing global specialty medicine franchises as a biotech CEO.
  • Mr. Kannan has successfully led blockbuster product launches across several therapeutic areas including oncology both in the U.S. and globally.
  • "I am very pleased to welcome Mr. Raj Kannan on board.

MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy

Retrieved on: 
Tuesday, May 2, 2023
Biotechnology, General Health, Mental Health, Health, Pharmaceutical, FOR, PFE, DRS, Patent Cooperation Treaty, Annual general meeting, Acquisition, Patient, Patent, Investment, Risk, Financial management, NYSE, FCM, GAD, GW Pharmaceuticals, Research, DSM-IV codes, Aerie Pharmaceuticals, FDA, Mental health, Social media, NOT, ALC, ALL, Annual Meetings of the International Monetary Fund and the World Bank Group, Multimedia, LSD, Trustee, NEO, MindMed, Drug development, SG, Spectrum, Clinical trial, Pfizer, Celgene, RBC Capital Markets, Invention, Jazz Pharmaceuticals, EF Hutton, Psychiatry, Management, Auction, Security (finance), Pharmaceutical industry, Medical device, Alcon, ADHD

The Company has launched www.ProtectMindMed.com to keep shareholders up to date on key developments leading up to the Annual Meeting.

Key Points: 
  • The Company has launched www.ProtectMindMed.com to keep shareholders up to date on key developments leading up to the Annual Meeting.
  • The full text of the Board’s letter to shareholders, which can be viewed and downloaded here , follows:
    Thank you for your investment in MindMed.
  • Your vote at the Company’s 2023 Annual General Meeting of Shareholders, scheduled for June 15, 2023, is critically important this year.
  • Shareholders will receive proxy materials directly via the preferred method, hard copy or email, specific to each shareholder’s account.

MindMed Files Preliminary Proxy Statement for 2023 Annual Meeting

Retrieved on: 
Tuesday, April 18, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, LLP, Chairperson, Medicine, Annual Meetings of the International Monetary Fund and the World Bank Group, GW Pharmaceuticals, Bristol Myers Squibb, Celgene, BMY, NYSE, Cooley LLP, Acquisition, Alcon, Aerie Pharmaceuticals, Patient, Hoskin, Annual general meeting, Our Boarding House, CFO, Jazz Pharmaceuticals, Growth, NEO, MindMed, FCM, Pharmaceutical industry, Management

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has filed its preliminary proxy materials with the U.S. Securities and Exchange Commission (“SEC”) in connection with the 2023 Annual General Meeting of Shareholders (the “Annual Meeting”), which has not yet been scheduled.

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has filed its preliminary proxy materials with the U.S. Securities and Exchange Commission (“SEC”) in connection with the 2023 Annual General Meeting of Shareholders (the “Annual Meeting”), which has not yet been scheduled.
  • In the preliminary proxy statement, MindMed sets forth its highly qualified slate of candidates for election to the Company’s Board of Directors (the “Board”) at the Annual Meeting.
  • He currently serves as a board member at Seagen Inc. (NASDAQ: SGEN) and Forte Biosciences, Inc. (NASDAQ: FBRX).
  • The Company looks forward to continuing to communicate with shareholders as our Annual Meeting approaches.

Nanoscope Therapeutics Appoints Industry Veteran Vicente Anido Jr., Ph.D., as a Strategic Advisor

Retrieved on: 
Monday, March 20, 2023
Virginia University, Aerie, University, Doctor of Philosophy, West Virginia University, ISTA, Retina, Bausch & Lomb, Aerie Pharmaceuticals, Patient, Ophthalmology, ISTA Pharmaceuticals, Entrepreneurship, Therapy, Vince, Atomic de Broglie microscope, Pharmaceutical industry, Pharmacy

DALLAS, March 20, 2023 /PRNewswire/ -- Nanoscope Therapeutics Inc. , a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced the appointment of Vicente Anido Jr., Ph.D., as a Strategic Advisor to the Company's Board and Management.

Key Points: 
  • DALLAS, March 20, 2023 /PRNewswire/ -- Nanoscope Therapeutics Inc. , a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced the appointment of Vicente Anido Jr., Ph.D., as a Strategic Advisor to the Company's Board and Management.
  • His deep experience and accomplishments in building and commercializing profitable ophthalmic companies will provide valuable guidance to support our clinical and corporate strategy.
  • As an ophthalmology industry leader, Dr. Anido Jr. brings over three decades of ophthalmic experience and will assist Nanoscope in its path towards the potential commercialization of MCO-010.
  • Dr. Anido Jr. holds a Ph.D. in Pharmaceutical Sciences from the University of Missouri, Kansas City and an M.S.

Mr. David Gryska Appointed to Forte Biosciences Board of Directors

Retrieved on: 
Thursday, January 12, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Bristol Myers Squibb, Aerie Pharmaceuticals, Biotechnology, Senior, Celgene, Paul, Acquisition, GW Pharmaceuticals, Management, Incyte

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), announced today that Mr. David Gryska has been appointed to the Forte Biosciences Board of Directors.

Key Points: 
  • Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), announced today that Mr. David Gryska has been appointed to the Forte Biosciences Board of Directors.
  • Mr. Gryska was previously the Chief Financial Officer and Executive Vice President at Incyte.
  • Prior to joining Incyte, Mr. Gryska held the position of Chief Financial Officer and Senior Vice President at Celgene prior to its acquisition by Bristol-Myers Squibb.
  • Mr. Gryska commented, “I am very pleased to join Paul and the Board of Forte.

Intergalactic Therapeutics Appoints Theresa G.H. Heah, M.D., M.B.A., as Chief Executive Officer

Retrieved on: 
Friday, January 6, 2023
Business administration, Kriyā, Management, ESMT, California Institute for Quantitative Biosciences, Therapy, Research, Drug development, University of London, Pfizer, AAV, Guy Goodwin, Kings, Johns Hopkins School of Medicine, Norwest Venture Partners, Growth, Patient, Ophthalmology, King's College, Degenerative disease, Investment, Intergalactic, Biogen, University, ATP, School, European School, Bayer, Applied Genetic Technologies Corporation, Aerie Pharmaceuticals, Pharmaceutical industry, Medical device, Neuroscience, Allergan, Sanofi, Operation, Medicine

BOSTON, Jan. 6, 2023 /PRNewswire/ -- Intergalactic Therapeutics , a company focused on transforming medicine through non-viral gene therapy, announced today the appointment of Theresa G.H.

Key Points: 
  • BOSTON, Jan. 6, 2023 /PRNewswire/ -- Intergalactic Therapeutics , a company focused on transforming medicine through non-viral gene therapy, announced today the appointment of Theresa G.H.
  • Heah, M.D., M.B.A., as Chief Executive Officer (CEO).
  • Dr. Ehlers, who is Chief Scientific Officer of Apple Tree Partners (ATP) and a Venture Partner at the firm, was the founding CEO of Intergalactic Therapeutics and led its incubation.
  • At ATP, he has led investments in ATP portfolio companies including Ascidian Therapeutics, Aulos Bioscience, Intergalactic Therapeutics, and Replicate Bioscience.

Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business

Retrieved on: 
Tuesday, November 22, 2022
Pharmaceutical, Health, Optical, Slate, Skadden, Social change, Pressure, Lazard, File, Approximation error, Duane syndrome, Retina, U.S. Department of Justice Office of Legislative Affairs, US, NYSE, State, Quality of life, Economy, Research, Acquisition, Fried, Frank, Harris, Shriver & Jacobson, Cataract, Glaucoma, Eye, Quality control, Aerie Pharmaceuticals, COVID-19, Goldman Sachs, History, Disease, Public expenditure, Patient, U.S. Department of Defense Strategy for Operating in Cyberspace, Security (finance), Risk management, Aerie, Alcon, Novartis

This transaction helps bolster Alcons presence in the ophthalmic pharmaceutical space with its growing portfolio of commercial products and development pipeline.

Key Points: 
  • This transaction helps bolster Alcons presence in the ophthalmic pharmaceutical space with its growing portfolio of commercial products and development pipeline.
  • Alcon has a rich history in the ophthalmic pharmaceutical space rooted in a deep understanding of Eye Care Professionals.
  • We are excited to add Aeries significant technical expertise to Alcon R&D, which enhances our efforts to build a compelling portfolio of ophthalmic pharmaceuticals.
  • Alcon has also acquired a pipeline of ophthalmic pharmaceutical product candidates with the opportunity to leverage Aeries existing research and development capabilities.